- Home
- WIW vs ZVRA Comparison
WIW vs ZVRA Comparison
Compare WIW & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WIW | ZVRA |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 472.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | WIW | ZVRA |
|---|---|---|
| Price | $8.61 | $9.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 259.2K | ★ 553.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 11.14% | N/A |
| EPS Growth | N/A | ★ 34.27 |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | ★ $23,612,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $44.19 |
| P/E Ratio | ★ N/A | $7.73 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.33 | $6.19 |
| 52 Week High | $9.03 | $13.16 |
Technical Indicators
Market Signals| Indicator | WIW | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 56.44 |
| Support Level | $8.60 | $8.61 |
| Resistance Level | $8.62 | $9.70 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 17.78 | 83.88 |
Price Performance
Historical ComparisonAbout WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income. Capital appreciation, when consistent with current income, is a secondary investment objective. The fund operates as a single operating segment, which is an investment portfolio.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.